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I thoroughly enjoyed reading the research article by
Yamakawa et al. [1]. They reported the possible survival
benefit of anticoagulant therapy in septic patients with
coagulopathy and/or a severe condition. This result was
consistent with former studies [2, 3]. However, I have
some concerns regarding the increase in bleeding adverse
events. Though the differences were not statistically
significant, the bleeding rates tended to increase in the
treated groups and the rate of bleeding requiring
transfusion was between 13 and 27 %. I wonder why the
incidence was so high in this study. Recombinant throm-
bomodulin and antithrombin were the two most popular
anticoagulants in Japan and they were the dominant anti-
coagulants in this study. Eguchi et al. [4] reported that
serious bleeding was recognized in 121 cases out of 1787
sepsis-induced disseminated intravascular coagulation
(DIC) patients treated with recombinant thrombomodulin
(6.8 %). We have also reported the incidence was 5.36 %
in 1026 sepsis-induced DIC patients who underwent anti-
thrombin supplementation [5]. One possible explanation
for the high incidence of bleeding in Yamakawa et al.’s
study was the longer observation period. Eguchi et al. and
we observed the incidence of bleeding for 28 days after
treatment, whereas Yamakawa et al. might have calculated
it for up to 100 days (not clearly stated). Since the use of
anticoagulants was usually no more than one week
(thrombomodulin less than 7 days, antithrombin less than
6 days), I do not think the late phase bleeding should be
included. It is reasonable to think that sustained DIC or a
very severe condition lasting more than one month might
contribute to an increased risk of bleeding. Since past
studies revealed that inappropriate doses significantly in-
crease the incidence, we were very careful on this point.
Therefore, the recent studies performed in Japan have re-
peatedly demonstrated that the incidence did not increase
with anticoagulant therapy [4, 5]. Thus, we would like to
see the short-term bleeding incidence in Yamakawa et al.’s
study. In addition, since Umemura et al. [3] reported that
the incidence was substantially different depending on
the agent used, information regarding which anticoag-
ulants were responsible for the increased bleeding
would also be appreciated.
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We thank Professor Iba for his valuable and insightful
comments regarding the bleeding complications asso-
ciated with anticoagulant therapy for sepsis-induced dis-
seminated intravascular coagulation (DIC). As Prof. Iba
mentioned, the frequency of bleeding complications in
our study [1] was relatively high compared with those in
previous studies [3–5]. Prof. Iba considered that the
higher frequency of bleeding complications might be
attributable to the longer observation period but in our
registry study incidences of bleeding were recorded only
during 7 days after ICU admission. What then was
responsible for the relatively high incidence of bleeding
complications in our study? In the present study, we
defined the bleeding complications as any bleeding
events including the occurrence of intracranial he-
morrhage, transfusion requirements related to bleeding,
and bleeding requiring surgical intervention. However,
most of the bleeding complications in this study were,
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indeed, transfusion requirements related to bleeding.
Because transfusion therapy was applied at the discretion
of the attending physician based on the treatment princi-
ples of each hospital, it is possible that different transfu-
sion principles might lead to an unexpectedly increased
incidence of transfusion requirements.
Another possible explanation for the high incidence of
bleeding in our study is the combination therapy with
two anticoagulant agents. Among 1247 patients in the
anticoagulant group, 633 patients (50.7 %) were treated
with a combination of more than two anticoagulant
agents and this was associated with significantly higher
risk of bleeding complications (17.2 % for combination
use versus 13.0 % for single use). Also, because the risks
of bleeding complications in this study were different
according to the anticoagulants used (unadjusted odds
ratio [OR] with 95 % confidence interval [CI] 2.65 [2.07–
3.39] for antithrombin, 1.48 [1.14–1.92] for recombinant
thrombomodulin, 1.98 [1.45–2.70] for serine protease
inhibitors, 1.50 [0.94–2.41] for heparin), the types of anti-
coagulants might be responsible for the high incidence of
bleeding complications in the treatment group.
Again, we thank Professor Iba for his insightful com-
ments and providing valuable data. Bleeding complica-
tions are one of the greatest concerns associated with
anticoagulant therapy. Decisions on the utilization of
anticoagulant therapy depend on the balance between
efficacy and safety of the therapy. We recognize that the
design of the present study is not sufficient to provide
definitive evidence for indications of anticoagulant therapy
in sepsis. Further investigations are needed to delineate
the optimal types, indications, dosages, and durations of
anticoagulant therapy to gain the maximum survival bene-
fits with minimal risk of bleeding complications.
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